Ionis Pharmaceuticals Inc. (IONS) Chairman Stanley T. Crooke Sells 11,000 Shares of Stock
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $36.61, for a total value of $402,710.00. Following the completion of the sale, the chairman now owns 35,029 shares in the company, valued at approximately $1,282,411.69. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) opened at 34.26 on Friday. The company’s market capitalization is $4.14 billion. Ionis Pharmaceuticals Inc. has a 1-year low of $19.59 and a 1-year high of $65.34. The company has a 50-day moving average price of $32.65 and a 200 day moving average price of $32.31.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. The business had revenue of $38.50 million for the quarter, compared to analyst estimates of $38.52 million. Ionis Pharmaceuticals had a negative return on equity of 126.88% and a negative net margin of 128.94%. The company’s revenue was down 68.0% on a year-over-year basis. Equities research analysts anticipate that Ionis Pharmaceuticals Inc. will post ($1.11) EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in IONS. Parametric Risk Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals during the first quarter valued at about $106,000. Rockefeller Financial Services Inc. bought a new position in Ionis Pharmaceuticals during the second quarter worth $114,000. Opera Trading Capital raised its position in Ionis Pharmaceuticals by 150.0% in the first quarter. Opera Trading Capital now owns 2,892 shares of the company’s stock worth $117,000 after buying an additional 1,735 shares in the last quarter. US Bancorp DE raised its position in Ionis Pharmaceuticals by 37.8% in the second quarter. US Bancorp DE now owns 5,952 shares of the company’s stock worth $139,000 after buying an additional 1,634 shares in the last quarter. Finally, GAM Holding AG raised its position in Ionis Pharmaceuticals by 118.5% in the second quarter. GAM Holding AG now owns 7,727 shares of the company’s stock worth $180,000 after buying an additional 4,191 shares in the last quarter. Institutional investors and hedge funds own 89.58% of the company’s stock.
Several equities research analysts have commented on IONS shares. Needham & Company LLC restated a “buy” rating and issued a $55.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, July 14th. Wells Fargo & Co. reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, August 19th. Janney Montgomery Scott started coverage on Ionis Pharmaceuticals in a research report on Wednesday, September 28th. They set a “buy” rating and a $47.00 price target on the stock. Piper Jaffray Cos. boosted their price target on Ionis Pharmaceuticals from $36.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 10th. Finally, Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 11th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $42.92.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.